LTPA2019506I1 - Nenukleozidinės reversinės transkriptazės inhibitoriai - Google Patents

Nenukleozidinės reversinės transkriptazės inhibitoriai

Info

Publication number
LTPA2019506I1
LTPA2019506I1 LTPA2019506C LTPA2019506C LTPA2019506I1 LT PA2019506 I1 LTPA2019506 I1 LT PA2019506I1 LT PA2019506 C LTPA2019506 C LT PA2019506C LT PA2019506 C LTPA2019506 C LT PA2019506C LT PA2019506 I1 LTPA2019506 I1 LT PA2019506I1
Authority
LT
Lithuania
Prior art keywords
reverse transcriptase
transcriptase inhibitors
nucleoside reverse
nucleoside
inhibitors
Prior art date
Application number
LTPA2019506C
Other languages
English (en)
Original Assignee
Merck Canada Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTPA2019506(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Canada Inc. filed Critical Merck Canada Inc.
Publication of LTPA2019506I1 publication Critical patent/LTPA2019506I1/lt
Publication of LTC2552902I2 publication Critical patent/LTC2552902I2/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
LTPA2019506 2010-03-30 2019-04-11 Nenukleozidinės reversinės transkriptazės inhibitoriai LTC2552902I2 (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31882410P 2010-03-30 2010-03-30
US32157310P 2010-04-07 2010-04-07
PCT/CA2011/000320 WO2011120133A1 (en) 2010-03-30 2011-03-28 Non-nucleoside reverse transcriptase inhibitors

Publications (2)

Publication Number Publication Date
LTPA2019506I1 true LTPA2019506I1 (lt) 2019-04-25
LTC2552902I2 LTC2552902I2 (lt) 2019-12-10

Family

ID=44710363

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP15157348.2T LT2924034T (lt) 2010-03-30 2011-03-28 Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių
LTPA2019506 LTC2552902I2 (lt) 2010-03-30 2019-04-11 Nenukleozidinės reversinės transkriptazės inhibitoriai
LTPA2019507C LTC2924034I2 (lt) 2010-03-30 2019-04-11 Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP15157348.2T LT2924034T (lt) 2010-03-30 2011-03-28 Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTPA2019507C LTC2924034I2 (lt) 2010-03-30 2019-04-11 Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių

Country Status (44)

Country Link
US (2) US8486975B2 (lt)
EP (2) EP2552902B1 (lt)
JP (2) JP5281718B2 (lt)
KR (1) KR101421861B1 (lt)
CN (1) CN102971308B (lt)
AR (1) AR080859A1 (lt)
AU (1) AU2011235568B2 (lt)
BR (1) BR112012024691B1 (lt)
CA (1) CA2794377C (lt)
CL (1) CL2012002744A1 (lt)
CO (1) CO6630126A2 (lt)
CR (1) CR20120503A (lt)
CY (3) CY1118774T1 (lt)
DK (2) DK2552902T3 (lt)
DO (1) DOP2012000256A (lt)
EA (1) EA024804B1 (lt)
EC (1) ECSP12012201A (lt)
ES (2) ES2609636T3 (lt)
FI (1) FIC20190021I1 (lt)
GE (1) GEP20156368B (lt)
HK (2) HK1175471A1 (lt)
HN (1) HN2012002039A (lt)
HR (2) HRP20150427T1 (lt)
HU (4) HUE025336T2 (lt)
IL (2) IL222030A (lt)
LT (3) LT2924034T (lt)
LU (1) LUC00114I2 (lt)
MA (1) MA34170B1 (lt)
ME (2) ME02570B (lt)
MX (1) MX2012011379A (lt)
MY (1) MY163979A (lt)
NI (1) NI201200146A (lt)
NL (1) NL300980I2 (lt)
NO (2) NO2019019I1 (lt)
NZ (1) NZ602670A (lt)
PE (1) PE20130158A1 (lt)
PL (2) PL2924034T3 (lt)
PT (2) PT2552902E (lt)
RS (2) RS54017B1 (lt)
SG (1) SG184347A1 (lt)
SI (2) SI2552902T1 (lt)
TN (1) TN2012000455A1 (lt)
TW (1) TWI458719B (lt)
WO (1) WO2011120133A1 (lt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024804B1 (ru) * 2010-03-30 2016-10-31 Мерк Кэнэда Инк. Ненуклеозидные ингибиторы обратной транскриптазы, композиции, их содержащие, и их применение
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
BR112015005997A8 (pt) 2012-09-26 2023-04-11 Merck Sharp & Dohme Composto
JO3470B1 (ar) * 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
WO2014089140A1 (en) 2012-12-05 2014-06-12 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
BR112016011605A8 (pt) * 2013-11-22 2023-04-25 Merck Sharp & Dohme Composição de um inibidor de transcriptase reversa não nucleosídeo
KR101803671B1 (ko) * 2013-12-04 2017-11-30 머크 샤프 앤드 돔 코포레이션 역전사효소 억제제의 제조 방법
EP3125894B1 (en) * 2014-04-01 2020-09-09 Merck Sharp & Dohme Corp. Prodrugs of hiv reverse transcriptase inhibitors
CN108367008B (zh) 2015-12-02 2021-04-30 默沙东公司 包含多拉韦林、富马酸替诺福韦二吡呋酯和拉米夫定的药物组合物
WO2018175271A1 (en) * 2017-03-24 2018-09-27 Merck Sharp & Dohme Corp. Formulation for parenteral administration
AU2018255954B2 (en) 2017-04-18 2024-04-04 Cipla Limited Combination therapy for use in treating retroviral infections
WO2019157087A1 (en) 2018-02-06 2019-08-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
CN110801455B (zh) * 2019-11-12 2020-06-02 河北医科大学第二医院 用于治疗mrsa的药物组合物及其应用
CN114163309B (zh) * 2021-12-27 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体的制备方法
CN114349690B (zh) * 2022-02-15 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
WO2004085406A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
CN1946680B (zh) 2004-04-23 2011-04-06 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
US20090264425A1 (en) 2004-12-22 2009-10-22 Pfizer Limited Chemical compounds
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
WO2007045572A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag N-phenyl phenylacetamide non-nucleoside reverse transcriptase inihibitors
KR20080056220A (ko) 2005-10-19 2008-06-20 에프. 호프만-라 로슈 아게 페닐-아세트아마이드 nnrt 저해제
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
WO2009067166A2 (en) * 2007-11-20 2009-05-28 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
EA024804B1 (ru) * 2010-03-30 2016-10-31 Мерк Кэнэда Инк. Ненуклеозидные ингибиторы обратной транскриптазы, композиции, их содержащие, и их применение

Also Published As

Publication number Publication date
PL2552902T3 (pl) 2015-10-30
LUC00114I1 (lt) 2019-04-17
MX2012011379A (es) 2012-11-30
EP2924034B1 (en) 2016-11-02
HUE031785T2 (en) 2017-08-28
EP2552902B1 (en) 2015-03-11
ECSP12012201A (es) 2012-10-30
ME02181B (me) 2015-10-20
CL2012002744A1 (es) 2012-12-14
FIC20190021I1 (fi) 2019-04-17
HK1209121A1 (en) 2016-03-24
AU2011235568B2 (en) 2013-09-12
EP2924034A1 (en) 2015-09-30
US20130296382A1 (en) 2013-11-07
HUE025336T2 (en) 2016-03-29
RS55505B1 (sr) 2017-05-31
SG184347A1 (en) 2012-11-29
CA2794377C (en) 2015-06-16
TN2012000455A1 (en) 2014-01-30
CY1118774T1 (el) 2017-07-12
PL2924034T3 (pl) 2017-07-31
EA201290976A1 (ru) 2013-03-29
HN2012002039A (es) 2015-08-24
ES2536295T3 (es) 2015-05-22
HUS1900022I1 (hu) 2019-05-28
NL300980I2 (nl) 2021-06-17
CR20120503A (es) 2013-01-09
HK1175471A1 (en) 2013-07-05
PT2924034T (pt) 2017-01-06
NL300980I1 (nl) 2019-04-24
SI2924034T1 (sl) 2017-05-31
JP2013510800A (ja) 2013-03-28
TW201139409A (en) 2011-11-16
CO6630126A2 (es) 2013-03-01
PT2552902E (pt) 2015-06-02
AU2011235568A1 (en) 2012-11-01
MA34170B1 (fr) 2013-04-03
CY2019026I1 (el) 2020-05-29
ES2609636T3 (es) 2017-04-21
EP2552902A1 (en) 2013-02-06
JP2013209405A (ja) 2013-10-10
MY163979A (en) 2017-11-15
KR20120128703A (ko) 2012-11-27
CY2019025I2 (el) 2019-11-27
CN102971308B (zh) 2015-02-04
US8486975B2 (en) 2013-07-16
NI201200146A (es) 2013-03-18
LUC00114I2 (lt) 2020-07-10
AR080859A1 (es) 2012-05-16
CA2794377A1 (en) 2011-10-06
ME02570B (me) 2017-06-20
DOP2012000256A (es) 2012-12-15
NO2019018I1 (no) 2019-04-24
HRP20161680T1 (hr) 2017-01-27
KR101421861B1 (ko) 2014-07-22
CY2019026I2 (el) 2020-05-29
LTC2552902I2 (lt) 2019-12-10
SI2552902T1 (sl) 2015-10-30
HRP20150427T1 (hr) 2015-07-03
RS54017B1 (en) 2015-10-30
WO2011120133A1 (en) 2011-10-06
BR112012024691A2 (pt) 2019-07-02
IL233334A0 (en) 2014-09-01
JP5886790B2 (ja) 2016-03-16
IL222030A (en) 2014-07-31
EA024804B1 (ru) 2016-10-31
PE20130158A1 (es) 2013-02-28
LTPA2019507I1 (lt) 2019-04-25
CY2019025I1 (el) 2019-11-27
CN102971308A (zh) 2013-03-13
US20110245296A1 (en) 2011-10-06
HUS1900021I1 (hu) 2019-05-28
IL233334A (en) 2015-09-24
DK2552902T3 (en) 2015-06-15
LTC2924034I2 (lt) 2020-10-12
EP2552902A4 (en) 2013-09-04
DK2924034T3 (en) 2017-02-06
TWI458719B (zh) 2014-11-01
LT2924034T (lt) 2016-12-27
GEP20156368B (en) 2015-09-25
JP5281718B2 (ja) 2013-09-04
NZ602670A (en) 2014-09-26
BR112012024691B1 (pt) 2020-11-17
NO2019019I1 (no) 2019-04-24

Similar Documents

Publication Publication Date Title
LTPA2019506I1 (lt) Nenukleozidinės reversinės transkriptazės inhibitoriai
SMT201500271B (it) Inibitori di neprilisina
DK3178818T3 (da) Pyrazolylquinoxalinkinasehæmmere
DK2371923T3 (da) Aflejringshæmmer
CO6970602A2 (es) Inhibidores de quinasa
DK2710007T3 (da) Kinasehæmmere
DK2448938T3 (da) Pyrimidinoner som pi3k-inhibitorer
DK2920149T3 (da) 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf
DK3196202T3 (da) Heterocyclylaminer som pi3k-inhibitorer
DK2421825T3 (da) Azetidinyldiamider som monoacylglycerollipase-inhibitorer
BR112013025761A2 (pt) inibidores de hsp90
BR112012019494A2 (pt) dispositivo elétrico
DE112011103500A5 (de) CVT-Getriebe
DK2531657T3 (da) Offshore-fundament
BR112013005966A2 (pt) refrigerador
RU2016124545A (ru) Композиция ненуклеозидного ингибитора обратной транскриптазы
DK2564056T3 (da) Turbine
BR112013012958A2 (pt) inibidores integrin ligado com quinase
DK2527666T3 (da) Ekspansionsanker
ES1073868Y (es) Turbina chaves-2
ES1075477Y (es) Taco expansible
FIU20100135U0 (fi) Pikakiinnike
UA21702S (uk) Напівтерка штукатурна
FIU20100537U0 (fi) Halkaisulaite
ITBS20100097A1 (it) Turbina